Information Provided By: 
Fly News Breaks for December 7, 2018
VNDA
Dec 7, 2018 | 08:03 EDT
Citi analyst Joel Beatty raised his price target for Vanda Pharmaceuticals to $47 and keeps a Buy rating on the shares citing the "strong" Phase 2 tradipitant gastroparesis results. The analyst also raised his probability of approval to 65% from 40%.
News For VNDA From the Last 2 Days
VNDA
Apr 19, 2024 | 11:12 EDT
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Intra-Cellular Therapies... To see the rest of the story go to thefly.com. See Story Here
VNDA
Apr 17, 2024 | 16:32 EDT
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here
VNDA
Apr 17, 2024 | 11:59 EDT
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here
VNDA
Apr 17, 2024 | 10:25 EDT
VNDA
Apr 17, 2024 | 09:05 EDT
